Study of ST-1898 in Advanced Renal Cell Carcinoma
A phase 1/2 trial of ST-1898 tablets in renal cell carcinoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, active and no longer recruiting.
Overview
Study of ST-1898 in Advanced Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT06127238 by Beijing Scitech-Mq Pharmaceuticals Limited, with 90 participants enrolled, started 2023-02-07 and due to reach its primary completion in 2025-12. Interventions recorded: ST-1898 tablets.
Similar pages
not linked directly; found by shared links- TrialA Study of ST-1898 for Unresectable or Metastatic Melanoma
Shares Beijing Scitech-Mq Pharmaceuticals and the tag pipeline.
- TrialStudy of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Shares Beijing Scitech-Mq Pharmaceuticals and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.
- TrialAB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Shares Renal cell carcinoma and the tag pipeline.
- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Shares Renal cell carcinoma and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Renal cell carcinoma and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma and the tag pipeline.
- TrialTT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Renal cell carcinoma and the tag pipeline.